Ahmed M. Salman
Also known as: Ahmed M. Salman
University of Oxford, University of Oxford Kellogg College, Leiden University Medical Center, Ain Shams University Faculty of Science, European Molecular Biology Laboratory
Research areas: Medicine · Public Health, Environmental and Occupational Health · Malaria Research and Control · Immunotherapy and Immune Responses · SARS-CoV-2 and COVID-19 Research
0000-0002-9259-7339
About
Dr. Ahmed M. Salman is senior Immunologist-Vaccinologist/Principal Investigator at The Jenner Institute. Fellow and advisor of Clinical Medicine at Kellogg College. Immunology instructor at University of Oxford, UK.
Dr. Salman is working in Professor Adrian Hill’s Lab at the Jenner Institute in the Pre-erythrocytic Malaria group. Dr. Salman’s work is mainly to identify and assess new target antigens as vaccine candidates for infectious diseases caused by human and veterinary pathogens (including Malaria, COVID-19, T. Solium) using advanced immunology, vaccinology, molecular biology, genome editing, protein expression, and vaccine manufacturing technologies. The promising antigens are used as target antigens and expressed either as viral vector vaccines to mainly induce cellular immune response or as viral like particle (VLP) to induce a massive humoral immune response.
Dr Salman took his BSc degree in Biochemistry at Ain Shams University in Cairo, Egypt in 2006 and from then until late 2011 was an instructor at the Department of Biochemistry, Faculty of Science, Ain Shams University. He completed a successful Master’s degree there on tuberculosis immunology in 2011. Most of that laboratory work was done while he worked at Statens Serum Institut in Copenhagen, Denmark, which is a major centre for mycobacterial vaccine research. In 2011 Dr Salman won a PhD scholarship at the European Virtual Malaria Institute programme “EVIMalaR” funded by the European Commission and EMBL at Heidelberg, Germany. In 2012 Dr. Salman started his D.Phil (PhD) in clinical medicine at the University of Oxford in Professor Adrian Hill’s Lab in Jenner Institute in collaboration with Professor Chris Janse and Professor Shahid Khan at the Leiden University Medical Centre in The Netherlands aiming for the identification and assessment of novel human malaria vaccines.
Dr Salman produced his DPhil thesis in October 2014 and the DPhil degree in Clinical Medicine was awarded to him in May 2015 from the University of Oxford. The most important recent impact of his work has been on antigen down-selection for vaccine clinical trials. Three novel antigens have been funded to go to GMP manufacture and clinical trials. This work has been filed in a Malaria vaccination’s patent with an application number: PCT/GB2014/053077 (URL: https://patents.google.com/patent/WO2015052543A3/en).
In addition he has a major contribution on another promising new P. vivax malaria sporozoite vaccine that is about to move to GMP manufacture and clinical trials. Since April 2020 Dr. Ahmed Salman became a part of the broad Jenner Institute research group working on the SARS-CoV-2 vaccine.
Employment
-
University of Oxford Immunology instructor2018 - Present
-
University of Oxford Kellogg College Junior Research Fellow at Kellogg College, University of Oxford2017 - Present
-
Ain Shams University Faculty of Science Holding a position of a Lecturer2015 - Present
-
University of Oxford Doctor of Immunology and Vaccinology2015 - Present
-
University of Oxford Post-doctoral Immunologist - Vaccinology2015 - 2017
-
St. Cross College, University of Oxford D.Phil student of Clinical Medicine2012 - 2015
-
Leids Universitair Medisch Centrum Visiting pre-doctoral fellow2012 - 2015
-
Ain Shams University Faculty of Science Holding a position of Assistant Lecturer2011 - 2015
-
Ain Shams University Faculty of Science Instructor of practical courses2010 - 2011
-
Al-Azhar University Faculty of Medicine Instructor of practical courses2009 - 2011
-
Ain Shams University Faculty of Science Demonstrator (instructor) teaching practical courses of undergraduate students2007 - 2011
Education
-
University of Oxford Post-doctoral Immunologist - Vaccinology2015 - Present
-
St. Cross College, University of Oxford Doctor of Philosophy (D.Phil) in Clinical Medicine2012 - 2015
-
Leids Universitair Medisch Centrum PhD fellow2012 - 2015
-
European Molecular Biology Laboratory Visiting pre-doctoral fellow under the EVIMalaR’s International PhD Program and EMBL International PhD Program2011 - 2015
-
Ain Shams University Faculty of Science M.Sc. degree in Biochemistry/Immunology2009 - 2011
-
Ain Shams University Faculty of Science Pre-master degree in Biochemistry2007 - 2008
-
Ain Shams University Faculty of Science B.Sc. Degree in Biochemistry2002 - 2006
Projects & Funding
Projects & funding information is unavailable.
Publications (43)
- Preclinical Evaluation of the SMNP-Adjuvanted R21 Malaria Vaccine Across Multiple Mouse Strains Save
- Efficacy and Response of R21/Matrix-M in Malaria Vaccine: A Systematic Review and Meta-Analysis of Clinical Trials Save
- SET1B Drives Sustained HIF activity and Disease Progression in Clear Cell Renal Cell Carcinoma. Save
- Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development Save
- Injectable core-shell microspheres deliver prime-boost immunisation in a single shot Save
- Insights on the Regeneration Potential of Müller Glia in the Mammalian Retina Save
- Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites Save
- COVID-19 vaccines: Global challenges and prospects forum recommendations. Save
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Save
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Save
- Discovery of four new B-cell protective epitopes for malaria using Q beta virus-like particle as platform Save
- Dissection-independent production of a protective whole-sporozoite malaria vaccine Save
- Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters Save
- Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. Save
- Discovery of four new B-cell protective epitopes for malaria using Q beta virus-like particle as platform Save
- Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria Save
- A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages Save
- Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice. Save
- DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. Save
- Prime and target immunization protects against liver-stage malaria in mice. Save